Intensive blood pressure control to <130/80 mmHg may reduce major adverse cardiovascular events across stages II to IV of cardiovascular-kidney-metabolic syndrome.
2
The cluster randomized trial involved 33,736 participants aged 40 and older with hypertension, followed for a median of 3.02 years.
3
The intervention group achieved significant systolic BP reductions of 21.4 to 26.2 mmHg across syndrome stages.
4
All-cause mortality decreased in stages II and III, but not in stage IV, with hypotension occurring more frequently in the intensive treatment group.
5
The study's limitations include potential residual confounding and classification accuracy issues due to reliance on clinical measures.
